Ligand Pharmaceuticals (LGND) Deferred Taxes (2011 - 2026)

Ligand Pharmaceuticals has disclosed Deferred Taxes across 16 years of filings, most recently posting $13.5 million for Q1 2026.

• Deferred Taxes for Q1 2026 came in at $13.5 million, up 53.01% year-over-year; the trailing twelve-month figure through Mar 2026 was -$18.0 million (down 140.72% YoY), and the FY2025 annual result was -$22.7 million, down 243.57% from the prior year.
• Deferred Taxes came in at $13.5 million for Q1 2026 at Ligand Pharmaceuticals, up from -$10.6 million in the prior quarter.
• In the past five years, Deferred Taxes ranged from a high of $20.7 million in Q2 2024 to a low of -$46.3 million in Q4 2022.
• The 5-year median for Deferred Taxes is $325000.0 (2025), against an average of -$1.5 million.
• Peak annual rise in Deferred Taxes reached 922.71% in 2022, while the deepest fall reached 12000.51% in 2022.
• Ligand Pharmaceuticals' Deferred Taxes stood at -$46.3 million in 2022, then surged by 89.34% to -$4.9 million in 2023, then soared by 357.18% to $12.7 million in 2024, then sank by 183.29% to -$10.6 million in 2025, then soared by 228.01% to $13.5 million in 2026.
• The last three Deferred Taxes figures came in at $13.5 million (Q1 2026), -$10.6 million (Q4 2025), and -$21.3 million (Q3 2025), per Business Quant data.